Medication Adherence in Older People With Psychosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by Veterans Medical Research Foundation.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
Veterans Medical Research Foundation
ClinicalTrials.gov Identifier:
NCT00071604
First received: October 29, 2003
Last updated: May 3, 2013
Last verified: April 2008
  Purpose

This study will determine whether Medication Adherence Therapy (MAT) can improve medication adherence and lower the risk of rehospitalization in older patients with psychosis.


Condition Intervention
Psychotic Disorders
Schizophrenia
Behavioral: Medication Adherence Therapy
Behavioral: Friendly Support Group

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: Medication Adherence in Older Psychotic People

Resource links provided by NLM:


Further study details as provided by Veterans Medical Research Foundation:

Estimated Enrollment: 240
Study Start Date: September 2002
Estimated Study Completion Date: May 2007
Detailed Description:

Psychoses are among the most common and serious psychiatric disorders. Currently, the most effective treatment for psychoses involves the use of antipsychotic or neuroleptic medications. Unfortunately, pharmacologic regimens often do not achieve their goals because of poor medication adherence. Nonadherence to antipsychotic treatment is a considerable public health problem that leads to myriad clinical and economic burdens, including psychotic relapse, increased clinic and emergency room visits, and rehospitalization.

Participants in this study are randomly assigned to receive either MAT or supportive treatment for 12 weeks. MAT is given in 15 sessions and consists of motivational interviewing, education, and social skills and behavior modification. Individual MAT sessions are held in Weeks 1 and 12; small group sessions take place in Weeks 2 through 11. Three monthly booster group sessions begin in Week 16. Participants are assessed at baseline and at 3, 6, and 12 months. Medication adherence, psychopathology, quality of life, medication side effects, health beliefs, and functioning are assessed.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • DSM-IV criteria for schizophrenia or schizoaffective disorder
  • Outpatient status at the time of enrollment
  • Currently prescribed maintenance treatment with antipsychotic medication (typical or atypical, oral or depot)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00071604

Locations
United States, California
Division of Geriatric Psychiatry Center (University of California, San Diego)
San Diego, California, United States, 92161
Sponsors and Collaborators
Veterans Medical Research Foundation
Investigators
Principal Investigator: Jonathan Lacro, PharmD VA San Diego Healthcare System & University of California, San Diego
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00071604     History of Changes
Other Study ID Numbers: R01 MH62849, R01MH062849, DATR A4-GPS
Study First Received: October 29, 2003
Last Updated: May 3, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Psychotic Disorders
Mental Disorders
Schizophrenia
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on August 28, 2014